Selzentry

(Maraviroc 300 qd)

PreclinicalSmall molecule

GSK

Selzentry is one of 4 small molecule programs targeting HIV Prevention. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

HIV PreventionTerminated

HIV PreventionPreclinical

Terminated

Competition

Competitive Landscape

4 competitors in HIV Prevention

#DrugCompanyPhaseTrials

Alhydrogel Adjuvant

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 2

GLA-SE Adjuvant

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 3

Selzentry

GSK

Preclinical

1 4

Pre-Exposure Prophylaxis (prep)

NNew York University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

HIV Prevention1 trial

Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women

Terminated·EEmory University·N/A·NCT02333045·4 enrolled

Regulatory

FDA Approval Timeline[4]

Nov 4, 2016

SELZENTRY

NDA NDA208984

Nov 4, 2016

SELZENTRY

NDA NDA022128

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Maraviroc 300 qd. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Maraviroc 300 qd compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Maraviroc 300 qd. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA208984). U.S. Food & Drug Administration.
[5]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GSK

Selzentry

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

HIV Prevention1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News